long intergenic non-protein coding RNA 1267Genealiases: []
Q-omics provides the consensus-scored LINC01267 profile across patient tissues and cancer cell-line models. LINC01267 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, LINC01267 is differentially expressed in 12, with the highest sampling consensus in LUAD. Additionally, LINC01267 RNA expression shows 9,582 significant gene co-expression associations, with the highest sampling consensus in HNSC. Together, these results highlight UCEC, LUAD, and HNSC as cancer lineages where LINC01267 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01267 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01267 survival associations across molecular data types. LINC01267 RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01267 RNA expression–survival associations across cancer types. High LINC01267 expression shows unfavorable associations in KIRC, but favorable associations in UCEC, CESC, BLCA, HNSC and UVM. The UCEC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for LINC01267 RNA expression.
This table summarizes LINC01267 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01267. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01267 shows lower tumor expression in LUAD, LUSC, BRCA and UCEC and higher tumor expression in THCA and COAD. The LUAD box plot shows higher LINC01267 RNA expression in normal versus tumor tissue (log2 FC = −0.652, t-test p < 0.001).
This table shows molecular features associated with LINC01267 in patient tissues and cancer cell lines. In patient samples, LINC01267 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set.
